Abbott Laboratories (NYSE: ABT) has reported Q4 FY21 adjusted EPS of $1.32, down from $1.45 a year ago but better than the consensus of $1.21.
- Q4 sales of $11.5 billion increased 7.2% on a reported basis and 7.7% on an organic basis, beating the consensus of $10.71 billion.
- Worldwide sales, excluding COVID-19 testing-related sales, increased 9.6% on a reported basis and 10.3% on an organic basis.
- Global COVID-19 testing-related sales were $2.3 billion. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
- Medical Devices sales increased 15.1% to $3.75 billion on a reported basis and 15.9% organically, driven by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care.
- Outlook: Abbott projects FY22 adjusted EPS of at least $4.70, compared to the consensus of $4.78.
- The company projects Q1 FY22 adjusted EPS of at least $1.50, above the consensus of $1.13.
- FY22 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion.
- Price Action: ABT shares are down 1.03% at $122.00 during the premarket session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.